GPT and Insulin resistance: The study revealed that ertugliflozin was effective at lowering TG levels from (260 ± 96.1 mg/dL) to (195 ± 80.5 mg/dL) (P = .003), ALT levels from (86.6 ± 50.4 U/dL) to (34.4 ± 23.0 U/dL) (P < .001) and insulin resistance HOMA-IR levels from (3.99 ± 0.53) to (3.10 ± 0.45) (P = .001).